1,849 results match your criteria Combined B-Cell and T-Cell Disorders


[Therapeutic effect of Compound Qinlan Oral Liquid on treating combining disease with syndrome of human coronavirus pneumonia with pestilence attacking lung syndrome].

Zhongguo Zhong Yao Za Zhi 2020 Apr;45(7):1473-1480

Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.

The aim of this paper was to investigate the therapeutic effect of Compound Qinlan Oral Liquid recommended by Provincial Novel Coronary Virus Pneumonia Treatment Scheme on the treatment of BALB/c mice with combining disease with syndrome of human coronavirus pneumonia with pestilence attacking lung syndrome and to explore its clinical application in the treatment of novel coronavirus pneumonia, and to provide laboratory data support for clinical Chinese medicine. According to the classification of syndromes of novel coronavirus pneumonia by the national competent department of traditional Chinese medicine, this study determined that human coronavirus 229 E(HCoV-229 E)-infected mouse model of cold and dampness syndrome can be used to study human coronavirus pneumonia combined with pestilence attacking the lung syndrome model. This model is suitable for simulating traditional Chinese medicine treatment of common disease syndromes in Novel Coronavirus Pneumonia Diagnosis and Treatment program(trial implementation of the sixth edition). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19540/j.cnki.cjcmm.20200303.402DOI Listing

Histology-Independent Signature Distinguishes Kikuchi-Fujimoto Disease/Systemic Lupus Erythematosus-Associated Lymphadenitis From Benign and Malignant Lymphadenopathies.

Am J Clin Pathol 2020 May 5. Epub 2020 May 5.

Department of Pathology, Stanford University School of Medicine, Stanford, CA.

Objectives: Kikuchi-Fujimoto disease (KFD) and systemic lupus erythematosus (SLE) are benign entities with histologic features that raise concern about malignancy and infection. We searched for a histology-independent KFD/SLE signature relying on only immunophenotype and basic clinical characteristics.

Methods: A histology-independent KFD/SLE signature was generated using 975 excised lymph nodes with flow immunophenotyping, including 16 cases of KFD/SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcp/aqaa036DOI Listing

Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency.

Allergol Immunopathol (Madr) 2020 Apr 26. Epub 2020 Apr 26.

Department of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig City, Al Sharqia Governorate, Egypt. Electronic address:

Background: Activated Phospho-Inositide 3 (PI3) Kinases Delta syndrome (APDS) can underlie primary immune deficiency. The prevalence and phenotypic characterization of these patients are not well described in Egypt.

Objectives: To describe patients with APDS in hospitalized children with recurrent respiratory tract infections with suspected primary immune deficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aller.2019.12.006DOI Listing

Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.

Emerg Microbes Infect 2020 Dec;9(1):727-732

Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwide. Up to now, according to official data released by the Chinese health commission, the number of newly diagnosed patients has been declining, and the epidemic is gradually being controlled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/22221751.2020.1746199DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170333PMC
December 2020

Age Distribution of Multiple Functionally Relevant Subsets of CD4+ T Cells in Human Blood Using a Standardized and Validated 14-Color EuroFlow Immune Monitoring Tube.

Front Immunol 2020 27;11:166. Epub 2020 Feb 27.

Translational and Clinical Research Program, Centro de Investigación del Cáncer (CIC) and Instituto de Biología Molecular y Celular del Cancer (IBMCC), CSIC-University of Salamanca (USAL), Salamanca, Spain.

CD4+ T cells comprise multiple functionally distinct cell populations that play a key role in immunity. Despite blood monitoring of CD4+ T-cell subsets is of potential clinical utility, no standardized and validated approaches have been proposed so far. The aim of this study was to design and validate a single 14-color antibody combination for sensitive and reproducible flow cytometry monitoring of CD4+ T-cell populations in human blood to establish normal age-related reference values and evaluate the presence of potentially altered profiles in three distinct disease models-monoclonal B-cell lymphocytosis (MBL), systemic mastocytosis (SM), and common variable immunodeficiency (CVID). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2020.00166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056740PMC
February 2020

The case for severe combined immunodeficiency (SCID) and T cell lymphopenia newborn screening: saving lives…one at a time.

Immunol Res 2020 02;68(1):48-53

Jeffrey Modell Foundation, 780 Third Avenue, 47th Floor, New York City, NY, 10017, USA.

Severe combined immunodeficiency (SCID) is a group of syndromes resulting from genetic defects causing severe deficiency in T cell and B cell function. These conditions are life-threatening and result in susceptibility to serious infections. SCID is often fatal in the first year of life if not detected and properly treated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12026-020-09117-9DOI Listing
February 2020

[Clinicopathological features of T-lymphoblastic lymphoma with Langerhans cell histiocytosis in the same lymph node].

Zhonghua Bing Li Xue Za Zhi 2020 Feb;49(2):149-155

Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

To investigate the clinicopathological features, immunophenotypes, genetics and prognosis of T-lymphocyte lymphoma/myeloid sarcoma combined with Langerhans cell histiocytyosis (coexistence of T-LBL/MS and LCH). Clinical and pathological data of the 6 patients with coexistence of T-LBL/MS and LCH were analyzed, who were diagnosed at the Foshan Hospital of Sun Yat-sen University and the Friendship Hospital of Capital Medical University, from December 2013 to April 2019. The hematoxylin and eosin stain, immunohitochemistry (EnVision) and in situ hybridization were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2020.02.009DOI Listing
February 2020

B Cells Inhibit CD4 T Cell-Mediated Immunity to Infection in a Major Histocompatibility Complex Class II-Dependent Manner.

Infect Immun 2020 Apr 20;88(5). Epub 2020 Apr 20.

Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA

spp. are facultative intracellular bacteria notorious for their ability to induce a chronic, and often lifelong, infection known as brucellosis. To date, no licensed vaccine exists for prevention of human disease, and mechanisms underlying chronic illness and immune evasion remain elusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/IAI.00075-20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171242PMC

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.

Am J Hematol 2020 05 29;95(5):510-520. Epub 2020 Feb 29.

Stanford University School of Medicine, Stanford, California.

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other B-cell lymphomas, in phase 1 studies evaluating urelumab alone (NCT01471210) or combined with rituximab (NCT01775631). Sixty patients received urelumab (0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25757DOI Listing
May 2020
3.798 Impact Factor

Hepatocyte-derived IL-10 plays a crucial role in attenuating pathogenicity during the chronic phase of T. congolense infection.

PLoS Pathog 2020 02 3;16(2):e1008170. Epub 2020 Feb 3.

Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Bovine African Trypanosomosis is an infectious parasitic disease affecting livestock productivity and thereby impairing the economic development of Sub-Saharan Africa. The most important trypanosome species implicated is T. congolense, causing anemia as most important pathological feature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.ppat.1008170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018099PMC
February 2020

Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.

Hematol Oncol 2020 Apr 3;38(2):146-152. Epub 2020 Feb 3.

Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan.

Posttransplant lymphoproliferative disorder (PTLD) is a serious complication after hematopoietic stem cell transplantation (HSCT). Several studies of risk factors for PTLD have been reported; however, the probability of, and risk factors for, PTLD in patients with lymphoma is unknown. Japanese nationwide transplant registry data from 5270 patients with lymphoma after allogeneic HSCT were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2714DOI Listing

Immune dysregulation in patients with RAG deficiency and other forms of combined immune deficiency.

Blood 2020 Feb;135(9):610-619

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Traditionally, primary immune deficiencies have been defined based on increased susceptibility to recurrent and/or severe infections. However, immune dysregulation, manifesting with autoimmunity or hyperinflammatory disease, has emerged as a common feature. This is especially true in patients affected by combined immune deficiency (CID), a group of disorders caused by genetic defects that impair, but do not completely abolish, T-cell function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019000923DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046604PMC
February 2020

A Novel Mutation in a Taiwanese Patient With Normal T Regulatory Function Presenting With the CVID Phenotype Free of Autoimmunity-Analysis of all Genotypes and Phenotypes.

Front Immunol 2019 19;10:2833. Epub 2019 Dec 19.

Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

The T-cell receptor (TCR)/CD3 complex is crucial for T-cell development and regulation. In humans, , and gene defects cause severe combined T- and B-cell immunodeficiency. However, mutations alone lead to a less severe condition, which is mainly characterized by autoimmunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.02833DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930882PMC
December 2019

High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model.

Proc Natl Acad Sci U S A 2020 01 7;117(3):1666-1677. Epub 2020 Jan 7.

Department of Medicine (Oncology), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461;

Major efforts are underway to identify agents that can potentiate effects of immune checkpoint inhibition. Here, we show that ascorbic acid (AA) treatment caused genomewide demethylation and enhanced expression of endogenous retroviral elements in lymphoma cells. AA also increased 5-hydroxymethylcytosine (5hmC) levels of CD8+ T cells and enhanced their cytotoxic activity in a lymphoma coculture system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1908158117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983418PMC
January 2020

Immunotherapy for Multiple Myeloma.

Cancers (Basel) 2019 Dec 12;11(12). Epub 2019 Dec 12.

Department of Hematology, Nippon Medical School, Tokyo 113-8603, Japan.

Despite therapeutic advances over the past decades, multiple myeloma (MM) remains a largely incurable disease with poor prognosis in high-risk patients, and thus new treatment strategies are needed to achieve treatment breakthroughs. MM represents various forms of impaired immune surveillance characterized by not only disrupted antibody production but also immune dysfunction of T, natural killer cells, and dendritic cells, although immunotherapeutic interventions such as allogeneic stem-cell transplantation and dendritic cell-based tumor vaccines were reported to prolong survival in limited populations of MM patients. Recently, epoch-making immunotherapies, i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11122009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966649PMC
December 2019

Clinical characterization and prognosis of T cell acute lymphoblastic leukemia with high CRLF2 gene expression in children.

PLoS One 2019 12;14(12):e0224652. Epub 2019 Dec 12.

Department of Hematology, Children's Hospital of Chongqing Medical University, Chongqing, P.R. China.

It has been reported that overexpression of the CRLF2 gene is associated with poor outcomes in pediatric B cell acute lymphoblastic leukemia (B-ALL), but the incidence rates, clinical characteristics and outcomes of CRLF2 gene overexpression in pediatric T cell ALL (T-ALL) have not been systematically analyzed. In this study, CRLF2 mRNA expression levels and clinical and laboratory parameters in 63 pediatric T-ALL patients were detected at the Children's Hospital of Chongqing Medical University and Children's Hospital of Xianyang between February 2015 and June 2018. The patients were treated according to the modified St. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0224652PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907766PMC

MicroRNA profiling in canine multicentric lymphoma.

PLoS One 2019 11;14(12):e0226357. Epub 2019 Dec 11.

Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.

Lymphoma is the most common hematopoietic tumour in dogs and is remarkably similar to the human disease. Tumour biomarker discovery is providing new tools for diagnostics and predicting therapeutic response and clinical outcome. MicroRNAs are small non-coding RNAs that participate in post-transcriptional gene regulation and their aberrant expression can impact genes involved in cancer. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0226357PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905567PMC
March 2020
5 Reads

Combined manual and automated immunophenotypisation identified disease-specific peripheral blood immune subpopulations in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

Clin Exp Rheumatol 2019 Nov 20. Epub 2019 Nov 20.

Croatian Institute for Brain Research, Laboratory for Molecular Immunology, University of Zagreb School of Medicine, Zagreb, Croatia.

Objectives: Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are associated with abnormal immune cell functions. We combined manual and automated profiling in subpopulations of T-cells, B-cells and monocytes, in parallel to functional testing and clinical correlation.

Methods: Using flow cytometry, we analysed the expression of CCR4, CCR6 and CXCR5 on helper and cyotoxic T-cells, CD32B and CD86 on naïve and memory B-cells, and CCR1, CCR2, CCR4 and CXCR4 on monocytes in chronic high-disease activity patients to identify peripheral blood subpopulations. Read More

View Article

Download full-text PDF

Source
November 2019

Predominantly Antibody-Deficient Patients With Non-infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 Cells.

Front Immunol 2019 15;10:2593. Epub 2019 Nov 15.

Department of Immunology and Pathology, Central Clinical School, Monash University and The Alfred Hospital, Melbourne, VIC, Australia.

Patients with predominantly antibody deficiency (PAD) suffer from severe and recurrent infections that require lifelong immunoglobulin replacement and prophylactic antibiotic treatment. Disease incidence is estimated to be 1:25,000 worldwide, and up to 68% of patients develop non-infectious complications (NIC) including autoimmunity, which are difficult to treat, causing high morbidity, and early mortality. Currently, the etiology of NIC is unknown, and there are no diagnostic and prognostic markers to identify patients at risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.02593DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873234PMC
November 2019

Thymoma complicated with myasthenia gravis and Good syndrome - a therapeutic conundrum: a case report.

J Med Case Rep 2019 Nov 29;13(1):348. Epub 2019 Nov 29.

University Medical Unit, National Hospital of Sri Lanka, Colombo, Sri Lanka.

Background: Thymomas are known to be associated with myasthenia gravis and Good syndrome. Good syndrome is the association of thymoma with combined B cell and T cell immunodeficiency. The combination of all three diseases has not been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13256-019-2289-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883564PMC
November 2019

A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.

mBio 2019 11 26;10(6). Epub 2019 Nov 26.

Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China

Group A streptococcus (GAS) species are responsible for a broad spectrum of human diseases, ranging from superficial to invasive infections, and are associated with autoimmune disorders. There is no commercial vaccine against GAS. The clinical manifestations of GAS infection may be attributable to the large repertoire of virulence factors used selectively in different types of GAS disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/mBio.02600-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879722PMC
November 2019

BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19 B lymphocytes.

J Immunother Cancer 2019 11 21;7(1):313. Epub 2019 Nov 21.

Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.

Background: The standard treatment for epithelial ovarian carcinoma (EOC) is surgery followed by platinum/paclitaxel-based chemotherapy, but the overall survival rate is poor. The purpose of this study was to investigate the therapeutic potential of chemotherapy combined with inhibition of B and T lymphocyte attenuator (BTLA) for clinical use to treat EOC.

Methods: Initially, we evaluated the potential application of chemotherapy combined with anti-BTLA antibody in an animal model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0744-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868712PMC
November 2019

Suppression of autoreactive T and B lymphocytes by anti-annexin A1 antibody in a humanized NSG murine model of systemic lupus erythematosus.

Clin Exp Immunol 2020 Mar 4;199(3):278-293. Epub 2019 Dec 4.

Laboratory of Experimental Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.

Systemic lupus erythematosus is a chronic inflammatory disease which involves multiple organs. Self-specific B and T cells play a main role in the pathogenesis of lupus and have been defined as a logical target for selective therapy. The protein annexin A1 (ANX A1) is a modulator of the immune system involving many cell types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cei.13399DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008224PMC
March 2020
3.037 Impact Factor

Severe combined immunodeficiency pig as an emerging animal model for human diseases and regenerative medicines.

BMB Rep 2019 Nov;52(11):625-634

Department of Stem Cell and Regenerative Biotechnology, Humanized Pig Research Center (SRC), Konkuk University, Seoul 05029, Korea.

Severe combined immunodeficiency (SCID) is a group of inherited disorders characterized by compromised T lymphocyte differentiation related to abnormal development of other lymphocytes [i.e., B and/or natural killer (NK) cells], leading to death early in life unless treated immediately with hematopoietic stem cell transplant. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889892PMC
November 2019

Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma.

Hematol Oncol 2019 Dec 12;37(5):578-585. Epub 2019 Nov 12.

Department of Internal Medicine, Chulalongkorn University, Bangkok, Thailand.

Event free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly described in T cell lymphoma. We explored the implication of EFS24 as a predictor marker for peripheral T cell lymphoma (PTCL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2687DOI Listing
December 2019

Rituximab in treatment of anti-GBM antibody glomerulonephritis: A case report and literature review.

Medicine (Baltimore) 2019 Nov;98(44):e17801

Department of Nephrology & Hypertension, Dokkyo Medical University, Mibu, Tochigi.

Rationale: Anti-glomerular basement membrane (GBM) disease is a T cell-mediated disease that has a poor prognosis with conventional therapy. We tested rituximab as a primary therapy to reduce anti-GBM antibody produced by B cells.

Patient Concerns: A 53-year old woman with complaints of a fever, headache and abdominal discomfort showed renal failure with elevated anti-GBM antibody, and renal biopsy revealed crescentic necrotizing glomerulonephritis with linear immunoglobulin G (IgG) 1 deposition along GBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000017801DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946414PMC
November 2019

Recent updates on CAR T clinical trials for multiple myeloma.

Mol Cancer 2019 11 5;18(1):154. Epub 2019 Nov 5.

The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, 450008, China.

Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies have dramatically changed the natural history of multiple myeloma (MM). However, most patients eventually suffer a relapse and succumb to the disease. Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7) and light chains are in active development for therapy of refractory /relapsed (RR) MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-019-1092-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829852PMC
November 2019
1 Read
4.257 Impact Factor

A Multiplex, Droplet Digital PCR Assay for the Detection of T-Cell Receptor Excision Circles and Kappa-Deleting Recombination Excision Circles.

Clin Chem 2019 Oct 31. Epub 2019 Oct 31.

ARUP Institute for Clinical and Experimental Pathology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT.

Background: T-cell receptor excision circles (TREC) and κ-deleting recombination receptor excision circles (KREC) concentrations can be used to assess and diagnose immune deficiencies, monitor thymic and bone marrow immune reconstitution, or follow responses to drug therapy. We developed an assay to quantify TREC, KREC, and a reference gene in a single reaction using droplet digital PCR (ddPCR).

Methods: PCR was optimized for 3 targets: TREC, KREC, and ribonuclease P/MRP subunit p30 () as the reference gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2019.308171DOI Listing
October 2019
1 Read

Two Different Extranodal Lymphomas in an HIV Patient: A Case Report and Review of the Literature.

Case Rep Hematol 2019 26;2019:8959145. Epub 2019 Sep 26.

ENT and Audiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, Sant' Orsola Hospital, University of Bologna, Bologna, Italy.

Human immune deficiency virus- (HIV-) infected individuals present a higher risk of developing malignancies. Herein, we are presenting an unusual case of an untreated HIV patient, who developed two distinct lymphoproliferative disorders in a period of 4 years: a primary cutaneous T-cell lymphoma (PCTCL) and a diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), the latter developed while commencing combined antiretroviral therapy (cART). The two lymphomas also showed peculiar features: PCTCL are rarely described in HIV setting and particularly at such a low clinical stage, and the DLBCL showed uncommon cytology, non-GCB phenotype, EBER negativity, and absence of c-MYC translocation, all atypical features in this clinical context. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8959145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791282PMC
September 2019
1 Read

[Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].

Zhonghua Xue Ye Xue Za Zhi 2019 Sep;40(9):750-754

Department of Hematology, Henan Cancer Hospital; The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.

To improve the knowledge and experience of ibrutinib combined with CAR-T cells in the treatment of high-risk chronic lymphoblastic leukemia (CLL) patients or small lymphocytic lymphoma (SLL) with TP53 gene aberration. One case of del (17p) CLL patients with BCL-2 inhibitor resistance was treated with ibrutinib combined with CAR-T cells, successfully bridged to allogeneic hematopoietic stem cell transplantation (allo-HSCT) , and the relative literatures were reviewed. The patient was a young female with superficial lymph node enlarging at the beginning of the onset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.09.008DOI Listing
September 2019
3 Reads

Recurrent microdeletions at chromosome 2p11.2 are associated with thymic hypoplasia and features resembling DiGeorge syndrome.

J Allergy Clin Immunol 2020 Jan 7;145(1):358-367.e2. Epub 2019 Oct 7.

Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Ala. Electronic address:

Background: Thymic hypoplasia/aplasia occurs as a part of DiGeorge syndrome, which has several known genetic causes, and with loss-of-function mutations in forkhead box N1 (FOXN1).

Objective: We sought to determine the cause of selective T-cell lymphopenia with inverted kappa/lambda ratio in several kindreds.

Methods: Patients were identified through newborn screening for severe combined immunodeficiency using the T-cell receptor excision circle assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2019.09.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949372PMC
January 2020
2 Reads

Genetic mutations and immunological features of severe combined immunodeficiency patients in Iran.

Immunol Lett 2019 12 4;216:70-78. Epub 2019 Oct 4.

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

Background: Severe combined immunodeficiency (SCID) is the most severe form of primary immunodeficiency disorders that is characterized by impaired early T lymphocyte differentiation and is variably associated with abnormal development of other lymphocyte lineages. SCID can be caused by mutations in more than 20 different genes. Molecular diagnosis in SCID patients contributes to genetic counseling, prenatal diagnosis, treatment modalities, and overall prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.imlet.2019.10.001DOI Listing
December 2019
1 Read
2.512 Impact Factor

Flow Cytometry for Diagnosis of Primary Immune Deficiencies-A Tertiary Center Experience From North India.

Front Immunol 2019 11;10:2111. Epub 2019 Sep 11.

Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Flow cytometry has emerged as a useful technology that has facilitated our understanding of the human immune system. Primary immune deficiency disorders (PIDDs) are a heterogeneous group of inherited disorders affecting the immune system. More than 350 genes causing various PIDDs have been identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.02111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749021PMC
September 2019
3 Reads

A newly found homozygous mutation in recombination activating gene 1 in a patient with leaky severe combined immunodeficiency disorder.

Mol Biol Rep 2019 Dec 13;46(6):6571-6575. Epub 2019 Sep 13.

Department of Allergy & Clinical Immunology, Iran University of Medical Sciences, Tehran, Iran.

The recombination activating genes, including RAG1 and RAG2, are essential for V(D)J somatic recombination in lymphocytes. Leaky severe combined immunodeficiency disorder (SCID) is characterized by normal or intermediate T cells and normal to absent B cells associated with partial T cell and B cell dysfunction. We present a newly found RAG1 deficiency in a 21-year-old boy with leaky SCID. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11033-019-05031-yDOI Listing
December 2019
3 Reads
2.024 Impact Factor

A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice.

BMC Cancer 2019 Sep 13;19(1):914. Epub 2019 Sep 13.

Research Group GMP & T Cell Therapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Background: NY-BR-1 has been described as a breast cancer associated differentiation antigen with intrinsic immunogenicity giving rise to endogenous T and B cell responses. The current study presents the first murine tumor model allowing functional investigation of NY-BR-1-specific immune responses in vivo.

Methods: A NY-BR-1 expressing tumor model was established in DR4tg mice based on heterotopic transplantation of stable transfectant clones derived from the murine H2 compatible breast cancer cell line EO771. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-6102-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743128PMC
September 2019

A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients.

Nat Med 2019 09 9;25(9):1402-1407. Epub 2019 Sep 9.

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.

Natalizumab (NZM), a humanized monoclonal IgG4 antibody to α4 integrins, is used to treat patients with relapsing-remitting multiple sclerosis (MS), but in about 6% of the cases persistent neutralizing anti-drug antibodies (ADAs) are induced leading to therapy discontinuation. To understand the basis of the ADA response and the mechanism of ADA-mediated neutralization, we performed an in-depth analysis of the B and T cell responses in two patients. By characterizing a large panel of NZM-specific monoclonal antibodies, we found that, in both patients, the response was polyclonal and targeted different epitopes of the NZM idiotype. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41591-019-0568-2
Publisher Site
http://dx.doi.org/10.1038/s41591-019-0568-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795539PMC
September 2019
3 Reads

Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas.

Expert Rev Hematol 2019 11 5;12(11):927-935. Epub 2019 Sep 5.

Department of Medicine, Queen Mary Hospital, Hong Kong, China.

: Natural killer (NK)/T-cell lymphomas are aggressive malignancies that present predominantly in nasal and adjacent sites (nasal subtype), occasionally in skin, gastrointestinal tract and other tissues (non-nasal), and rarely as disseminated disease with a leukemic phase (aggressive NK-cell leukemia, or leukemia/lymphoma, subtype).: The diagnosis and treatment of NK/T-cell lymphoma are discussed, based on a PubMed literature search. The diagnostic criteria for NK/T-cell lymphoma are highlighted, followed by an update of the diagnostic and prognostic importance (on presentation, at interim and end-of-treatment) of plasma EBV DNA as a surrogate biomarker of lymphoma load. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1660640DOI Listing
November 2019
2 Reads

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.

BMC Cancer 2019 Aug 14;19(1):809. Epub 2019 Aug 14.

Department of Haematology, Toulouse-Oncopole University Cancer Institute (IUCT-O), 1 Avenue Irene Joliot-Curie, 31059, Toulouse, France.

Background: Eradication of minimal residual disease (MRD), at the end of Fludarabine-Cyclophosphamide-Rituximab (FCR) treatment, is a validated surrogate marker for progression-free and overall survival in chronic lymphocytic leukaemia. But such deep responses are also associated with severe immuno-depletion, leading to infections and the development of secondary cancers.

Methods: We assessed, blood MRD and normal immune cell levels at the end of treatment, in 162 first-line FCR patients, and analysed survival and adverse event. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5971-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694602PMC
August 2019
1 Read

Aggressive large B-cell lymphoma triggered by a parvovirus B19 infection in a previously healthy child.

Hematol Oncol 2019 Oct 25;37(4):483-486. Epub 2019 Aug 25.

Institute of Pediatric Hematology and Oncology, Hospices Civils de Lyon, Claude Bernard Lyon I University, Lyon, France.

In absence of red blood cells disease or immune defect, parvovirus B19 (PVB-19) is usually considered as a benign condition. Here, we report the case of a 10-year-old boy, previously healthy, presenting with a PVB-19 infection revealed by a bicytopenia and a voluminous axillary adenopathy. Pathophysiology examination showed reactional lymphoid population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2665DOI Listing
October 2019
2 Reads

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.

Lancet Haematol 2019 Oct 1;6(10):e521-e529. Epub 2019 Aug 1.

Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China. Electronic address:

Background: Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has been shown to have activity in patients with relapsed or refractory multiple myeloma. Reports have suggested that a small subgroup of less differentiated myeloma clones express CD19 and anti-CD19 CAR T-cell therapy has shown activity in some of these patients. We aimed to assess the activity and safety of a combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30115-2DOI Listing
October 2019
9 Reads

Beneficial effect of consolidative radiotherapy for patients with lymphoma and skeletal involvement.

Medicine (Baltimore) 2019 Aug;98(31):e16688

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

The objectives of this study were to analyze the clinical features of patients with bone involved lymphoma and identify the prognostic factors and to explore the optimized treatment strategy for bone involved lymphoma.A total of 1948 patients with lymphoma in our cancer center from September 2006 to October 2017 were retrospectively evaluated. Among these, 109 patients with skeletal involvement in lymphoma were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000016688DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708869PMC
August 2019
5 Reads
5.723 Impact Factor

Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma?

Int J Hematol Oncol Stem Cell Res 2019 Apr;13(2):102-107

Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA.

We report a case of a 76-year-old male with a history of relapsed and refractory diffuse large B-cell lymphoma (DLBCL).Our patient was initially treated with front line chemotherapy along with central nervous system (CNS) prophylaxis with complete response. He subsequently relapsed, was sensitive to second-line chemotherapy, and underwent autologous stem cell transplantation achieving a complete remission. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660481PMC
April 2019
3 Reads

Proteomic and histopathological characterisation of sicca subjects and primary Sjögren's syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkers.

Arthritis Res Ther 2019 07 31;21(1):181. Epub 2019 Jul 31.

Department of Oral Surgery and Oral Medicine, University of Oslo, Oslo, Norway.

Background: Mononuclear cell infiltration of exocrine glands, production of Ro/SSA and La/SSB autoantibodies, along with oral and ocular dryness, are characteristic features of primary Sjögren's syndrome (pSS). Non-SS sicca subjects, an underexplored group in relation to pSS, display similar sicca symptoms, with possible mild signs of inflammation in their salivary glands, yet with no serological detection of autoantibody production. In this study, we investigated inflammatory manifestations in the salivary gland tissue, tear fluid and saliva of non-SS subjects, as compared to pSS patients and healthy individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1961-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670195PMC
July 2019
4 Reads

The complementary role of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in diagnosis of Hodgkin's lymphoma.

Ann Diagn Pathol 2019 Oct 17;42:64-68. Epub 2019 Jun 17.

Faculty of Medicine, Mansoura University, Egypt.

Background: Hodgkin's Lymphoma (HL) is a peculiar subtype of lymphoid malignancies. The etiology of HL is still unknown. Insulin-like growth factor II mRNA-binding Protein 3 (IMP3) is a member of IMP family. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2019.06.006DOI Listing
October 2019

Blastic plasmacytoid dendritic cell neoplasm in the background of myeloproliferative disorder and chronic lymphocytic leukaemia.

BMJ Case Rep 2019 Jul 15;12(7). Epub 2019 Jul 15.

Hematology and Oncology, Albany Stratton VA Medical Center, Albany, New York, USA.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare haematological malignancy defined by concurrent expression of CD4, CD56, BCL-2 and CD123. The disease has a very poor prognosis and there are no well-established treatment guidelines. We describe a case of BPDCN in a 65-year-old female patient with myeloproliferative disorder (essential thrombocythemia) and chronic lymphocytic leukaemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-230332DOI Listing
July 2019
14 Reads

[The number and subgroups of lymphocytes in valve tissue of rheumatic heart disease combined with diabetes mellitus].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2019 Jun;35(6):552-556

Department of Cardiothoracic Surgery, Hospital of Cardiocerebral Vascular Diseases, General Hospital of Ningxia Medical University, Yinchuan 750000, China.

Objective To investigate the effect of diabetes mellitus on lymphocytes in rheumatic heart valve tissue and its mechanism. Methods Valve tissues of 40 patients undergoing heart valve replacement were collected, including 20 patients in rheumatic heart disease group (without diabetes) and 20 patients in diabetic group (rheumatic heart disease combined with diabetes). In addition, 20 cases of valve tissue from control group were collected. Read More

View Article

Download full-text PDF

Source
June 2019
5 Reads

Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy.

Eur J Immunol 2019 08 9;49(8):1147-1152. Epub 2019 Jul 9.

Leeds Institute of Medical Research at St James's, University of Leeds, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, LS9 7TF, UK.

The successful implementation of immunotherapies has provided new impetus in the fight against cancer. Antibody-mediated blockade of immune checkpoint molecules PD-1/PD-L1 and CTLA-4 has had a dramatic impact upon the treatment of previously intractable cancers such as malignant melanoma, while adoptive cell therapies using chimeric antigen receptor-bearing T cells have proven highly efficacious in B cell leukemia. Furthermore, significant progress has been made in understanding the mechanisms by which tumors evade or become resistant to these immunotherapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.201848058DOI Listing

Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.

Blood 2019 08 5;134(5):445-455. Epub 2019 Jun 5.

Department of Dermatology, Venereology and Allergy, University Medical Center Mannheim/Ruprecht Karls University of Heidelberg, Mannheim, Germany.

Therapeutic options for cutaneous T-cell lymphoma (CTCL) are limited and curative treatment regimens are not available. Thus, new targeted and well-tolerated therapeutic approaches are urgently needed. In this respect, we have recently shown that dimethyl fumerate (DMF) inhibits NF-κB acting as a survival factor in CTCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019001545DOI Listing
August 2019
8 Reads

Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome.

Acta Oncol 2019 Aug 25;58(8):1170-1177. Epub 2019 May 25.

b Experimental and Clinical Oncology, Department of Immunology, Genetics, and Pathology , Uppsala University , Uppsala , Sweden.

Patients with certain autoimmune diseases (AID) have an increased risk of developing diffuse large B-cell lymphoma (DLBCL). However, the occurrence of AID in patients with DLBCL as well as the impact of AID on outcome has not been extensively studied. The main purpose of this study was to establish the occurrence of AIDs in a population-based cohort of DLBCL patients and to compare outcomes in patients with or without AID treated with rituximab(R)-CHOP/CHOP-like treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2019.1619936DOI Listing
August 2019
8 Reads

Novel targets for the treatment of relapsing multiple myeloma.

Expert Rev Hematol 2019 07 3;12(7):481-496. Epub 2019 Jun 3.

b Department of Medical Science , University of Turin , Turin , Italy.

: Multiple myeloma (MM) is characterized by the high tendency to relapse and develop drug resistance. : This review focused on the main novel targets identified to design drugs for the treatment of relapsing MM patients. CD38 and SLAMF7 are the main surface molecules leading to the development of monoclonal antibodies (mAbs) recently approved for the treatment of relapsing MM patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1624158DOI Listing
July 2019
35 Reads